Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

Group 1 - Lilly has committed over $16 billion since 2020 to develop new manufacturing sites in the U.S. and Europe, with total manufacturing investments exceeding $18 billion when including updates to existing facilities [1][2] - The company is expanding its manufacturing capabilities to support the production of new medicines like Zepbound and Mounjaro, which target type 2 diabetes and obesity, respectively [2][5] - The expansion in Indiana's LEAP Research and Innovation District is expected to create 200 full-time jobs and over 5,000 construction jobs during development [3][4] Group 2 - The Indiana state government is partnering with Lilly on infrastructure improvements and workforce development initiatives to support the expansion project [4] - Lilly's investment is seen as a significant contribution to Indiana's economy, reinforcing the state's environment for innovation and skilled workforce [4][5] - The company aims to begin production at the Lebanon site by the end of 2026, with operations scaling up through 2028 [5]